Ser1906
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser1906  -  SHARP (human)

Site Information
tRRRNVRsVyAtMGD   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 23144003

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 )
Disease tissue studied:
lung cancer ( 1 ) , non-small cell lung cancer ( 1 )
Relevant cell line - cell type - tissue:

References 

1

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

2

Zhou J (2011) CST Curation Set: 12026; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY(YXXM) Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Tyr) p85 PI3K Binding Motif Antibody Cat#: 3821
Curated Info